Attempted suicide with liraglutide overdose did not induce hypoglycemia.
Nakanishi R, Hirose T, Tamura Y, Fujitani Y, Watada H.
Diabetes Res Clin Pract · journal article; case reports · DOI 10.1016/j.diabres.2012.10.017 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för liraglutide. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
25 hitsC-peptide response to glucagon challenge is correlated with improvement of early insulin secretion by liraglutide treatment.
Takabe M, Matsuda T, Hirota Y, Hashimoto N, Nakamura T, Sakaguchi K, Ogawa W, Seino S.
Diabetes Res Clin Pract · research support, non-u.s. gov't; journal article · DOI 10.1016/j.diabres.2012.09.036Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study.
Nauck M, Frid A, Hermansen K, Thomsen AB, During M, Shah N, Tankova T, Mitha I, Matthews DR.
Diabetes Obes Metab · comparative study; research support, non-u.s. gov't; review; journal article · DOI 10.1111/dom.12012A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo.
Scott DA, Boye KS, Timlin L, Clark JF, Best JH.
Diabetes Obes Metab · comparative study; research support, non-u.s. gov't; systematic review; network meta-analysis; journal article · DOI 10.1111/dom.12007Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection.
Hölscher C.
CNS Drugs · research support, non-u.s. gov't; review; journal article · DOI 10.2165/11635890-000000000-00000Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes.
Fujishima Y, Maeda N, Inoue K, Kashine S, Nishizawa H, Hirata A, Kozawa J, Yasuda T, Okita K, Imagawa A, Funahashi T, Shimomura I.
Cardiovasc Diabetol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/1475-2840-11-107Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme.
Niswender K, Pi-Sunyer X, Buse J, Jensen KH, Toft AD, Russell-Jones D, Zinman B.
Diabetes Obes Metab · clinical trial, phase iii; comparative study; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1111/j.1463-1326.2012.01673.xThe effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone.
Ohki T, Isogawa A, Iwamoto M, Ohsugi M, Yoshida H, Toda N, Tagawa K, Omata M, Koike K.
ScientificWorldJournal · comparative study; research-article; journal article · DOI 10.1100/2012/496453Effect of the GLP-1 analog liraglutide on satiation and gastric sensorimotor function during nutrient-drink ingestion.
Rotondo A, Janssen P, Mulè F, Tack J.
Int J Obes (Lond) · randomized controlled trial; journal article · DOI 10.1038/ijo.2012.101Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial.
Pratley RE, Nauck MA, Bailey T, Montanya E, Filetti S, Garber AJ, Thomsen AB, Furber S, Davies M, 1860-LIRA-DPP-4 Study Group.
Diabetes Care · research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.2337/dc11-2113[Liraglutide: new results in the treatment of type 2 diabetes mellitus].
Mateos JL, Wajchenberg BL.
Drugs Today (Barc) · review; journal article · DOI 10.1358/dot.2012.48(suppl.b).1876681Vesiculopustular dermatosis: an uncommon side-effect of liraglutide?
Besemer F, Verschoor AJ, Diamant M, Hoogma RP.
J Diabetes Complications · journal article; case reports · DOI 10.1016/j.jdiacomp.2012.05.018Liraglutide protects against amyloid-β protein-induced impairment of spatial learning and memory in rats.
Han WN, Hölscher C, Yuan L, Yang W, Wang XH, Wu MN, Qi JS.
Neurobiol Aging · research support, non-u.s. gov't; journal article · DOI 10.1016/j.neurobiolaging.2012.04.009Early intervention with liraglutide improves glucose tolerance without affecting islet microcirculation in young Goto-Kakizaki rats.
Wu L, Olverling A, Fransson L, Ortsäter H, Kappe C, Gao X, Sjöholm A.
Regul Pept · research support, non-u.s. gov't; journal article · DOI 10.1016/j.regpep.2012.05.091Effects of liraglutide on β-cell-specific glucokinase-deficient neonatal mice.
Shirakawa J, Tanami R, Togashi Y, Tajima K, Orime K, Kubota N, Kadowaki T, Goshima Y, Terauchi Y.
Endocrinology · research support, non-u.s. gov't; journal article · DOI 10.1210/en.2012-1165Liraglutide therapy beyond glycemic control: an observational study in Indian patients with type 2 diabetes in real world setting.
Kesavadev J, Shankar A, Krishnan G, Jothydev S.
Int J Gen Med · research-article; journal article · DOI 10.2147/ijgm.s27886The design of the liraglutide clinical trial programme.
Nauck MA.
Diabetes Obes Metab · review; journal article · DOI 10.1111/j.1463-1326.2012.01573.xEffect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes.
Horowitz M, Flint A, Jones KL, Hindsberger C, Rasmussen MF, Kapitza C, Doran S, Jax T, Zdravkovic M, Chapman IM.
Diabetes Res Clin Pract · research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/j.diabres.2012.02.016Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis.
Hunter K, Hölscher C.
BMC Neurosci · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/1471-2202-13-33Incretin-based therapies in clinical practice: from efficacy to effectiveness. Focus on liraglutide.
Ponzani P, Corsi A.
Minerva Endocrinol · journal articleThe human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species.
Nyborg NC, Mølck AM, Madsen LW, Knudsen LB.
Diabetes · research-article; journal article · DOI 10.2337/db11-0936An overview of the pharmacokinetics, efficacy and safety of liraglutide.
Bode B.
Diabetes Res Clin Pract · review; journal article · DOI 10.1016/j.diabres.2011.12.015The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide.
Barnett AH.
Diabetes Obes Metab · research support, non-u.s. gov't; review-article; review; journal article · DOI 10.1111/j.1463-1326.2011.01523.xGlp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet.
Mells JE, Fu PP, Sharma S, Olson D, Cheng L, Handy JA, Saxena NK, Sorescu D, Anania FA.
Am J Physiol Gastrointest Liver Physiol · research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1152/ajpgi.00274.2011The Akt/FoxO1/p27 pathway mediates the proliferative action of liraglutide in β cells.
Fang D, Huang Z, Guan H, Liu J, Yao B, Xiao H, Li Y.
Mol Med Rep · research support, non-u.s. gov't; journal article · DOI 10.3892/mmr.2011.607